Ruth A Roberts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6110795/publications.pdf

Version: 2024-02-01

33 papers 1,083

³⁹⁴⁴²¹ 19 h-index 32 g-index

34 all docs

34 docs citations

times ranked

34

1256 citing authors

#	Article	IF	CITATIONS
1	Tox-GAN: An Artificial Intelligence Approach Alternative to Animal Studies—A Case Study With Toxicogenomics. Toxicological Sciences, 2022, 186, 242-259.	3.1	23
2	Can We Panelize Seizure?. Toxicological Sciences, 2021, 179, 3-13.	3.1	9
3	A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria. Toxicology Research, 2021, 10, 203-213.	2.1	8
4	Species-Specific Urothelial Toxicity With an Anti-HIV Noncatalytic Site Integrase Inhibitor (NCINI) Is Related to Unusual pH-Dependent Physicochemical Changes. Toxicological Sciences, 2021, 183, 105-116.	3.1	1
5	DeepDILI: Deep Learning-Powered Drug-Induced Liver Injury Prediction Using Model-Level Representation. Chemical Research in Toxicology, 2021, 34, 550-565.	3.3	41
6	Justification for species selection for pharmaceutical toxicity studies. Toxicology Research, 2021, 9, 758-770.	2.1	37
7	A decade of toxicological trends: what the papers say. Toxicology Research, 2020, 9, 676-682.	2.1	3
8	Deep Learning on High-Throughput Transcriptomics to Predict Drug-Induced Liver Injury. Frontiers in Bioengineering and Biotechnology, 2020, 8, 562677.	4.1	24
9	Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation. Regulatory Toxicology and Pharmacology, 2020, 113, 104624.	2.7	22
10	New ideas for non-animal approaches to predict repeated-dose systemic toxicity: Report from an EPAA Blue Sky Workshop. Regulatory Toxicology and Pharmacology, 2020, 114, 104668.	2.7	33
11	Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia. MedChemComm, 2019, 10, 1379-1390.	3.4	15
12	Collaboration, competition and publication in toxicology: views of British Toxicology Society members. Toxicology Research, 2019, 8, 480-488.	2.1	1
13	Innovative models for in vitro detection of seizure. Toxicology Research, 2019, 8, 784-788.	2.1	6
14	Toxicogenomics: A 2020 Vision. Trends in Pharmacological Sciences, 2019, 40, 92-103.	8.7	116
15	Collaboration and competition: ethics in toxicology. Toxicology Research, 2018, 7, 576-585.	2.1	8
16	Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study. Experimental Biology and Medicine, 2018, 243, 228-236.	2.4	17
17	Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration. Experimental Biology and Medicine, 2018, 243, 1037-1045.	2.4	39
18	Understanding drug targets: no such thing as bad news. Drug Discovery Today, 2018, 23, 1925-1928.	6.4	20

#	Article	lF	Citations
19	Lessons Learned from Two Decades of Anticancer Drugs. Trends in Pharmacological Sciences, 2017, 38, 852-872.	8.7	74
20	Toxicology as an academic discipline in European Universities. Toxicology Letters, 2016, 254, 63.	0.8	8
21	Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward. Toxicological Sciences, 2015, 148, 332-340.	3.1	43
22	Quantifying the pharmaceutical industry's contribution to published 3Rs research 2002–2012. Toxicology Research, 2015, 4, 311-316.	2.1	1
23	Development and use of in vitro alternatives to animal testing by the pharmaceutical industry 1980–2013. Toxicology Research, 2015, 4, 1297-1307.	2.1	49
24	Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure?. Regulatory Toxicology and Pharmacology, 2015, 73, 737-746.	2.7	15
25	Reducing attrition in drug development: smart loading preclinical safety assessment. Drug Discovery Today, 2014, 19, 341-347.	6.4	74
26	Mouse hepatocyte response to peroxisome proliferators: dependency on hepatic nonparenchymal cells and peroxisome proliferator activated receptor \hat{l}_{\pm} (PPAR \hat{l}_{\pm}). Archives of Toxicology, 2001, 75, 357-361.	4.2	25
27	Species differences in response to diethylhexylphthalate: suppression of apoptosis, induction of DNA synthesis and peroxisome proliferator activated receptor alpha-mediated gene expression. Archives of Toxicology, 2000, 74, 85-91.	4.2	72
28	Role of hepatic non-parenchymal cells in the response of rat hepatocytes to the peroxisome proliferator nafenopin in vitro. Carcinogenesis, 2000, 21, 2159-2165.	2.8	34
29	Cytokines in non-genotoxic hepatocarcinogenesis. Carcinogenesis, 1999, 20, 1397-1402.	2.8	52
30	Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences. Archives of Toxicology, 1999, 73, 413-418.	4.2	77
31	Suppression of apoptosis and induction of DNA synthesis in vitro by the phthalate plasticizers monoethylhexylphthalate (MEHP) and diisononylphthalate (DINP): a comparison of rat and human hepatocytes in vitro. Archives of Toxicology, 1999, 73, 451-456.	4.2	38
32	Role for tumor necrosis factor? receptor 1 and interleukin-1 receptor in the suppression of mouse hepatocyte apoptosis by the peroxisome proliferator nafenopin. Hepatology, 1999, 30, 1417-1424.	7.3	41
33	Suppression of hepatocyte apoptosis and induction of DNA synthesis by the rat and mouse hepatocarcinogen diethylhexylphlathate (DEHP) and the mouse hepatocarcinogen 1,4-dichlorobenzene (DCB). Archives of Toxicology, 1998, 72, 784-790.	4.2	55